dc.contributor |
Landspitali - The National University Hospital of Iceland |
dc.contributor.author |
Ørnbjerg, Lykke Midtbøll |
dc.contributor.author |
Linde, Louise |
dc.contributor.author |
Georgiadis, Stylianos |
dc.contributor.author |
Horskjær Rasmussen, Simon |
dc.contributor.author |
Lindström, Ulf |
dc.contributor.author |
Askling, Johan |
dc.contributor.author |
Michelsen, Brigitte |
dc.contributor.author |
Di Giuseppe, Daniela |
dc.contributor.author |
Wallman, Johan K. |
dc.contributor.author |
Pavelka, Karel |
dc.contributor.author |
Závada, Jakub |
dc.contributor.author |
Nissen, Michael J |
dc.contributor.author |
Jones, Gareth T. |
dc.contributor.author |
Relas, Heikki |
dc.contributor.author |
Pirilä, Laura |
dc.contributor.author |
Tomšič, Matija |
dc.contributor.author |
Rotar, Ziga |
dc.contributor.author |
Geirsson, Árni Jón |
dc.contributor.author |
Guðbjörnsson, Björn |
dc.contributor.author |
Kristianslund, Eirik K. |
dc.contributor.author |
van sder Horst-Bruinsma, Irene |
dc.contributor.author |
Loft, Anne Gitte |
dc.contributor.author |
Laas, Karin |
dc.contributor.author |
Iannone, Florenzo |
dc.contributor.author |
Corrado, Addolorata |
dc.contributor.author |
Ciurea, Adrian |
dc.contributor.author |
Santos, Maria José |
dc.contributor.author |
Santos, Helena |
dc.contributor.author |
Codreanu, Catalin |
dc.contributor.author |
Akkoc, Nurullah |
dc.contributor.author |
Gunduz, Ozgul S. |
dc.contributor.author |
Glintborg, Bente |
dc.contributor.author |
Østergaard, Mikkel |
dc.contributor.author |
Lund Hetland, Merete |
dc.date.accessioned |
2022-10-22T01:04:00Z |
dc.date.available |
2022-10-22T01:04:00Z |
dc.date.issued |
2022-10-01 |
dc.identifier.citation |
Ørnbjerg , L M , Linde , L , Georgiadis , S , Horskjær Rasmussen , S , Lindström , U , Askling , J , Michelsen , B , Di Giuseppe , D , Wallman , J K , Pavelka , K , Závada , J , Nissen , M J , Jones , G T , Relas , H , Pirilä , L , Tomšič , M , Rotar , Z , Geirsson , Á J , Guðbjörnsson , B , Kristianslund , E K , van sder Horst-Bruinsma , I , Loft , A G , Laas , K , Iannone , F , Corrado , A , Ciurea , A , Santos , M J , Santos , H , Codreanu , C , Akkoc , N , Gunduz , O S , Glintborg , B , Østergaard , M & Lund Hetland , M 2022 , ' Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors : Data from the EuroSpA collaboration ' , Seminars in Arthritis and Rheumatism , vol. 56 , 152081 , pp. 152081 . https://doi.org/10.1016/j.semarthrit.2022.152081 |
dc.identifier.issn |
0049-0172 |
dc.identifier.other |
62301338 |
dc.identifier.other |
e1719022-b286-42ea-b10d-42c9dc65af01 |
dc.identifier.other |
85135923596 |
dc.identifier.other |
35985172 |
dc.identifier.other |
unpaywall: 10.1016/j.semarthrit.2022.152081 |
dc.identifier.uri |
https://hdl.handle.net/20.500.11815/3532 |
dc.description |
Funding Information: LMØ, LL, SG and SHR: research grants from Novartis; UL: none; DDG none; JKW: consultant of AbbVie, Amgen, Celgene, Eli Lilly and Novartis; BG: research grants from Pfizer, Abbvie and BMS; LP: consultant of Novartis Finland, UCB Pharma, Pfizer, Sanofi, BMS, AbbVie, Amgen, Celgene, Eli Lilly, Boehringer-Ingelheim, Mylan; KL: consulting and/or speaking fees from Amgen, Johnson and Johnson and Novartis; ACo: research grants, consulting and/or speaking fees from Amgen, Lilly, Pfizer, Boehringer Ingelheim; KP: speaker and consulting fees from Pfizer, MSD, BMS, UCB, Amgen, Egis, Roche, AbbVie; JZ: speaker and consulting fees from Abbvie, Elli-Lilly, Sandoz, Novartis, Egis, UCB; EKK: none; NA: speaking fees from Pfizer; ÖSG: none; HS: research grant from Sociedade Portuguesa de Reumatologia and speaker and/or consultancy fees from Abbvie, Janssen, Lilly, Novartis and Pfizer; MJN: consulting and/or speaking fees from AbbVie, Eli Lilly, Janssens, Novartis and Pfizer; BM: research grant from Novartis; GTJ: research grants from AbbVie, Pfizer, UCB, Amgen, GSK. Speaker fee from Janssen; HR: consulting and/or speaking fees from Abbvie, Celgene, Pfizer, UCB, and Viatris; MT: consulting and/or speaking fees from Abbvie, Amgen, Biogen, Eli Lilly, Janssen, Medis, MSD, Novartis, Pfizer, Sanofi, Sandoz-Lek; AJG: none; IHB: Consultant for Abbvie, UCB, MSD, Novartis, Lilly, unrestricted Grants received for investigator initiated studies from: MSD, Pfizer, AbbVie, UCB, fees received for Lectures from BMS, AbbVie, Pfizer, MSD ; JA: PI for agreements between Karolinska Institutet and Abbvie, Astra-Zeneca, BMS, Eli Lilly, Janssen, MSD, Pfizer, Roche, Samsung Bioepis, Sanofi, and UCB; FI: consulting and/or speaking from Abbvie, Amgen, AstraZeneca, BMS, Galapagos, Janssen, Lilly, MSD, Novartis, Pfizer, Roche and UCB; AGL: Research Grant from Novartis, and speaker and/or consultancy fees from AbbVie, Janssen, Lilly, MSD, Novartis, Pfizer, Roche, and UCB; ACi: consulting and/or speaking fees from AbbVie, Eli Lilly, Merck Sharp & Dohme, Novartis and Pfizer; MJS: speaker fees from Abbvie, AstraZeneca, Lilly, Novartis and Pfizer; CC: Speaker and consultancy fees from AbbVie, Amgen, Boehringer Ingelheim, Ewopharma, Lilly, Novartis, Pfizer; ZR: speaker or consultancy fees from Abbvie, Novartis, MSD, Medis, Biogen, Eli Lilly, Pfizer, Sanofi, Lek, Janssen; BjG: consulting and/or speaking fees from Amgen and Novartis; MØ: research grants from Abbvie, BMS, Merck, Celgene and Novartis, and speaker and/or consultancy fees from Abbvie, BMS, Boehringer-Ingelheim, Celgene, Eli-Lilly, Hospira, Janssen, Merck, Novartis, Novo, Orion, Pfizer, Regeneron, Roche, Sandoz, Sanofi and UCB; MLH: Research grants from Abbvie, Biogen, BMS, Celltrion, Eli Lilly, Janssen Biologics B.V, Lundbeck Fonden, MSD, Medac, Pfizer, Roche, Samsung Biopies, Sandoz, Novartis. Funding Information: This work was supported by Novartis Pharma AG . Publisher Copyright: © 2022 Copyright © 2022. Published by Elsevier Inc. |
dc.description.abstract |
Objectives: In patients with axial spondyloarthritis (axSpA) initiating their first tumor necrosis factor alpha-inhibitor (TNFi), we aimed to identify common baseline predictors of Ankylosing Spondylitis Disease Activity Score (ASDAS-CRP) inactive disease (primary objective) and clinically important improvement (CII) at 6 months, and drug retention at 12-months across 15 European registries. Methods: Baseline demographic and clinical characteristics were collected. Outcomes were investigated per registry and in pooled data using logistic regression analyses on multiply imputed data. Results: The consistency of baseline predictors in individual registries justified pooling the data. In the pooled dataset (n = 21,196), the 6-month rates for ASDAS inactive disease and ASDAS CII were 26% and 51%, and the 12-month drug retention rate 65% in patients with available data (n = 9,845, n = 6,948 and n = 21,196, respectively). Nine common baseline predictors of ASDAS inactive disease, ASDAS CII and 12-month drug retention were identified, and the odds ratios (95%-confidence interval) for ASDAS inactive disease were: age, per year: 0.97 (0.97–0.98), men vs. women: 1.88 (1.60–2.22), current vs. non-smoking: 0.76 (0.63–0.91), HLA-B27 positive vs. negative: 1.51 (1.20–1.91), TNF start year 2015–2018 vs. 2009–2014: 1.24 (1.06–1.45), CRP>10 vs. ≤10 mg/l: 1.49 (1.25–1.77), one unit increase in health assessment questionnaire (HAQ): 0.77 (0.58–1.03), one-millimeter (mm) increase in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) fatigue and spinal pain: 0.99 (0.99–1.00) and 0.99 (0.99–1.99), respectively Conclusion: Common baseline predictors of treatment response and adherence to TNFi could be identified across data from 15 European registries, indicating that they may be universal across different axSpA populations. |
dc.format.extent |
1393551 |
dc.format.extent |
152081 |
dc.language.iso |
en |
dc.relation.ispartofseries |
Seminars in Arthritis and Rheumatism; 56() |
dc.rights |
info:eu-repo/semantics/openAccess |
dc.subject |
Gigtarlæknisfræði |
dc.subject |
Ankylosing spondylitis disease activity score |
dc.subject |
Axial spondyloarthritis |
dc.subject |
Predictors |
dc.subject |
TNF-inhibitors |
dc.subject |
Severity of Illness Index |
dc.subject |
Spondylarthritis/drug therapy |
dc.subject |
Humans |
dc.subject |
Male |
dc.subject |
Tumor Necrosis Factor Inhibitors/therapeutic use |
dc.subject |
Female |
dc.subject |
Registries |
dc.subject |
Axial Spondyloarthritis |
dc.subject |
Spondylitis, Ankylosing/drug therapy |
dc.subject |
Anesthesiology and Pain Medicine |
dc.subject |
Rheumatology |
dc.title |
Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors : Data from the EuroSpA collaboration |
dc.type |
/dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/article |
dc.description.version |
Peer reviewed |
dc.identifier.doi |
10.1016/j.semarthrit.2022.152081 |
dc.relation.url |
http://www.scopus.com/inward/record.url?scp=85135923596&partnerID=8YFLogxK |
dc.contributor.department |
Internal Medicine and Emergency Services |
dc.contributor.department |
Faculty of Medicine |